May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Subconjunctival Nanoparticle Carboplatin in the Treatment of Transgenic Murine Retinoblastoma
Author Affiliations & Notes
  • S. J. Kang
    Ophthalmology, Emory University Eye Center, Atlanta, Georgia
  • C. Durairaj
    Pharmaceutical Sciences & Ophthalmology, Nebraska Medical Center, Omaha, Nebraska
  • U. B. Kompella
    Pharmaceutical Sciences & Ophthalmology, Nebraska Medical Center, Omaha, Nebraska
  • J. M. O'Brien
    Ophthalmology, University of California at San Francisco, San Francisco, California
  • K. Liu
    Ophthalmology, Emory University Eye Center, Atlanta, Georgia
  • H. E. Grossniklaus
    Ophthalmology, Emory University Eye Center, Atlanta, Georgia
  • Footnotes
    Commercial Relationships  S.J. Kang, None; C. Durairaj, None; U.B. Kompella, None; J.M. O'Brien, None; K. Liu, None; H.E. Grossniklaus, None.
  • Footnotes
    Support  NIH R24 EY017045-01, P30 EY06360, RPB
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 2017. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S. J. Kang, C. Durairaj, U. B. Kompella, J. M. O'Brien, K. Liu, H. E. Grossniklaus; Subconjunctival Nanoparticle Carboplatin in the Treatment of Transgenic Murine Retinoblastoma. Invest. Ophthalmol. Vis. Sci. 2008;49(13):2017. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the efficacy of subconjunctival nanoparticle carboplatin in the treatment of transgenic murine retinoblastoma.

Methods: : Dendrimeric nanoparticles loaded with carboplatin were prepared. LHβ-Tag mice were randomly assigned into 3 groups, and treated at 10 weeks of age. Each mouse received a single subconjunctival injection in one eye, and the opposite eye was left untreated as a control. Group 1 (nanoparticle group, 10 mice) received 37.5 mg/ml nanoparticle carboplatin (0.66 mg measured total dose). Group 2 (conventional group, 10 mice) received same concentration of conventional carboplatin, and group 3 (PBS group, 5 mice) received PBS. Mice were killed on day 22 after treatment. Eyes were serially sectioned, and retinal tumor burden was quantified by histopathologic analysis.

Results: : Mean tumor burden in the nanoparticle group was significantly smaller compared to the untreated eyes in the same mice (P < 0.02), conventional carboplatin-treated group (P < 0.02), and PBS treated group (P < 0.001). A single subconjunctival injection of conventional carboplatin did not show significant decrease in tumor burden compared to the PBS treated group (P = 0.82). No histologic evidence of toxicity was observed in any of the groups.

Conclusions: : A single injection of subconjunctival nanoparticle carboplatin was effective in the treatment of transgenic murine retinoblastoma with no associated toxicity.

Keywords: retinoblastoma • drug toxicity/drug effects • oncology 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×